AKT1 and cancer: Cancer therapies that inhibit phosphoinositide 3-kinase-protein kinase B- (PI3K-AKT)-mammalian target of rapamycin signaling are expanding in usage and development, as this pathway is frequently overactivated in malignancies of various organs.